Sanofi CEO re­it­er­ates R&D bet is best long-term ap­proach, ad­dress­es probe on mar­ket ma­nip­u­la­tion al­le­ga­tions

Al­though Sanofi CEO Paul Hud­son was at the Fi­nan­cial Times’ Glob­al Phar­ma and Biotech Sum­mit to talk about AI, there was no avoid­ing the ques­tions about its re­cent move to spin out its con­sumer unit as well as the in­ves­ti­ga­tion in France over al­leged mis­lead­ing fi­nan­cial com­mu­ni­ca­tions.

Hud­son re­it­er­at­ed that the con­sumer unit spin­out was all about Sanofi in­vest­ing in the sci­ence. But this was at the cost of aban­don­ing its earn­ings guid­ance for 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER